IR Banner

Press Releases

Date Title and Summary Additional Format
Jul 27, 2022
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
AUSTIN, Texas , July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022 . The company will host a conference call and
Jul 26, 2022
CEO Update: Interview with Lumos Pharma’s Chief Medical Officer, David B. Karpf, M.D.
Lumos Pharma CMO, David B. Karpf, M.D., walks us through his background and perspective on LUM-201. Q: When did you know you wanted to go into medicine – what drove you to that profession? A: My dad was an exceptional doctor, so I knew at age 5 that I wanted to be a physician.
May 16, 2022
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas , May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences: Event: H.C.
May 10, 2022
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold-- --Clinical Collaboration Initiated with Massachusetts General
May 5, 2022
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA AUSTIN, Texas , May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare
Apr 26, 2022
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
AUSTIN, Tex. , April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022 . The company will host a conference call and webcast
Apr 11, 2022
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-    Interim Data Anticipated by End of 2022    - -   Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, Texas , April 11, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare
Mar 23, 2022
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
AUSTIN, Texas , March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew , PhD, President and Chief Scientific Officer of Lumos Pharma , will participate in a panel
Mar 10, 2022
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022 AUSTIN, Texas , March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on
Mar 10, 2022
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas , March 10, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the 34 th Annual Roth Conference and the Maxim 2022 Virtual Growth Conference in
Displaying 11 - 20 of 67